- Stocks
- Healthcare
- NASDAQ: ASRT

Price (delayed)

$0.49

Market cap

$85.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$108.3M

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

ASRT's equity has surged by 90% since the previous quarter and by 25% year-on-year

The company's EPS has shrunk by 137% QoQ but it has surged by 73% YoY

ASRT's net income has dropped by 130% since the previous quarter but it has surged by 60% year-on-year

ASRT's debt is up by 45% year-on-year

Assertio Holdings's gross margin has decreased by 16% YoY

What are the main financial stats of ASRT

Market
Valuations
Earnings

Shares outstanding

173.79M

Market cap

$85.16M

Enterprise value

$108.3M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.81

Price to sales (P/S)

0.66

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.97

Revenue

$112.2M

EBIT

-$73.76M

EBITDA

-$48.59M

Free cash flow

-$44.74M

Per share
Balance sheet
Liquidity

EPS

-$0.64

Free cash flow per share

-$0.3

Book value per share

$0.61

Revenue per share

$0.74

TBVPS

$0.87

Total assets

$325.42M

Total liabilities

$220.12M

Debt

$84.17M

Equity

$105.3M

Working capital

$14.98M

Debt to equity

0.8

Current ratio

1.14

Quick ratio

0.92

Net debt/EBITDA

-0.48

Margins
Efficiency
Dividend

EBITDA margin

-43.3%

Gross margin

80%

Net margin

-57.8%

Operating margin

-51.7%

Return on assets

-19.8%

Return on equity

-80.6%

Return on invested capital

-167.3%

Return on capital employed

-34.1%

Return on sales

-65.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Assertio Holdings stock price performed over time

Intraday

4.26%

1 week

-14.04%

1 month

-5.77%

1 year

N/A

YTD

36.11%

QTD

-27.94%

How have Assertio Holdings's revenue and profit performed over time

Revenue

$112.2M

Gross profit

$89.76M

Operating income

-$58.02M

Net income

-$64.83M

Gross margin

80%

Net margin

-57.8%

ASRT's net income has dropped by 130% since the previous quarter but it has surged by 60% year-on-year

ASRT's net margin has dropped by 118% since the previous quarter but it is up by 31% year-on-year

Assertio Holdings's operating income has surged by 73% YoY and by 29% QoQ

ASRT's operating margin has soared by 54% YoY and by 33% QoQ

What is Assertio Holdings's growth rate over time

What is Assertio Holdings stock price valuation

P/E

N/A

P/B

0.81

P/S

0.66

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.97

The company's EPS has shrunk by 137% QoQ but it has surged by 73% YoY

ASRT's equity has surged by 90% since the previous quarter and by 25% year-on-year

The stock's P/B is 62% less than its 5-year quarterly average of 2.0 and 14% less than its last 4 quarters average of 0.9

ASRT's price to sales (P/S) is 48% lower than its 5-year quarterly average of 1.2 but 5% higher than its last 4 quarters average of 0.6

The revenue has declined by 42% year-on-year but it has increased by 6% since the previous quarter

How efficient is Assertio Holdings business performance

The company's return on sales has shrunk by 136% QoQ and by 10% YoY

The company's return on invested capital has shrunk by 120% QoQ

The ROE has plunged by 115% from the previous quarter but it has grown by 27% YoY

The ROA has dropped by 111% since the previous quarter but it is up by 29% year-on-year

What is ASRT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ASRT.

How did Assertio Holdings financials performed over time

The total assets is 48% more than the total liabilities

Assertio Holdings's quick ratio has surged by 88% QoQ but it has decreased by 5% YoY

ASRT's total liabilities has soared by 63% YoY but it is down by 11% QoQ

ASRT's debt is 20% smaller than its equity

ASRT's equity has surged by 90% since the previous quarter and by 25% year-on-year

The debt to equity has decreased by 47% from the previous quarter but it has increased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.